Skip to main content
. Author manuscript; available in PMC: 2013 Jun 4.
Published in final edited form as: Mol Pharm. 2012 May 15;9(6):1612–1619. doi: 10.1021/mp200612n

Figure 2.

Figure 2

CE-LIF traces of the exoglycosidase digestion based structural annotation of N-glycans present in the NCI reference standard monoclonal antibody (upper panel). The three lower panels show the relevant sections of CE-LIF traces showing the peaks corresponding the structures containing the α-1,3-Gal moieties of the N-glycans of the NCI reference standard monoclonal antibody (NCI) and two development-phase monoclonal antibody therapeutics (UTC 1 and UTC2). Exoglycosidase digestion enzyme combinations, separation conditions and bracketing standards were the same as of in Figure 1.